Aptahem’s patent family 2 in Europe has been finalized by validation in the 11 countries where applied
Aptahem AB (publ) announces today that in all countries in Europe where the company has applied for patent protection now have validated and approved the patent family 2. The patent has been published with patent number 3691655.With these validations of the approved patent application in Europe, the company’s drug candidate Apta-1 is now protected within patent family 2 in the following countries: Sweden, Great Britain, Germany, France, Spain, Italy, The Netherlands, Austria, Poland, Turkey and Switzerland. The patent protection is valid until the end of 2038. CEO Mikael Lindstam